Sagimet Biosciences Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Sagimet Biosciences Inc. (SGMT) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $11.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-11.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-11
- Sagimet Biosciences Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $11.00M, a 2.65% decline from fiscal 2024.
- Sagimet Biosciences Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $11.30M, a 54.79% increase from fiscal 2023.
- Sagimet Biosciences Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $7.30M, a 1.35% decline from fiscal 2022.
- Sagimet Biosciences Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $7.40M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $11.00M 10-K · filed 2026-03-11 |
| 2024-12-31 | $11.30M 10-K · filed 2026-03-11 |
| 2023-12-31 | $7.30M 10-K · filed 2025-03-12 |
| 2022-12-31 | $7.40M 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |